{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-012231","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.493568+00:00","generated_at":"2026-06-24T04:12:11.054340+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Voyager Therapeutics prioritizes tau/GBA1/SOD1-ALS pipeline, posts Q2 net loss of $19.1M","bullets":["Q2 collaboration revenue $0.7M (down from $1.4M YoY); net loss $19.1M vs $30.1M in Q2 2021.","Prioritized pipeline: tau antibody for Alzheimer's, GBA1 gene therapy for Parkinson's, SOD1 gene silencing for ALS.","Identified receptor for TRACER AAV capsid; AAV9-derived capsid shows 50-60x better brain transduction vs AAV9.","Catherine J. Mackey, Ph.D. (ex-Pfizer) appointed to Board of Directors, effective Aug 15, 2022.","Cash $148.1M expected to fund operations into 2024; Pfizer option decision by Oct 2022, Novartis by Mar 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-012231","json":"https://secwatch.observer/filing/0001558370-22-012231.json","markdown":"https://secwatch.observer/filing/0001558370-22-012231.md","text":"https://secwatch.observer/filing/0001558370-22-012231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000155837022012231/0001558370-22-012231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000155837022012231/vygr-20220804x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:12:11.054340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}